Canada - anglais - Health Canada

sandoz canada incorporated - granisetron (granisetron hydrochloride) - liquid - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - anglais - Health Canada

apotex inc - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - anglais - Health Canada

omega laboratories limited - granisetron (granisetron hydrochloride) - liquid - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - anglais - Health Canada

baxter corporation - mesna - solution - 100mg - mesna 100mg - protective agents

Canada - anglais - Health Canada

strides pharma canada inc - granisetron (granisetron hydrochloride) - solution - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - anglais - Health Canada

sandoz canada incorporated - granisetron (granisetron hydrochloride) - solution - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - anglais - Health Canada

natco pharma (canada) inc - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

États-Unis - anglais - NLM (National Library of Medicine)

akorn - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 1 g in 10 ml - levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology ). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known.

États-Unis - anglais - NLM (National Library of Medicine)

american regent, inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 200 mg in 1 ml - for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. for the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. none known.

États-Unis - anglais - NLM (National Library of Medicine)

leadiant biosciences, inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 1 g in 10 ml - carnitor ® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology ). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. carnitor ® (levocarnitine) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none